<SEC-DOCUMENT>0001193125-25-063669.txt : 20250326
<SEC-HEADER>0001193125-25-063669.hdr.sgml : 20250326
<ACCEPTANCE-DATETIME>20250326115646
ACCESSION NUMBER:		0001193125-25-063669
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20250326
FILED AS OF DATE:		20250326
DATE AS OF CHANGE:		20250326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		25771229

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d939010d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
March 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><U>Exhibit No.</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><U>Description</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><A HREF="d939010dex991.htm">Press Release dated March&nbsp;25, 2025 : Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><A HREF="d939010dex992.htm">Press Release dated March&nbsp;26, 2025 : Chlamydia vaccine candidate granted fast track designation by the US FDA </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: March&nbsp;26, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>/s/ <U>Alexandra Roger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d939010dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g939010g01m04.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple
sclerosis </I></FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat <FONT
STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Tolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability
accumulation in MS </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Tolebrutinib was granted <FONT COLOR="#7a00e6"><U>breakthrough therapy</U></FONT> designation by the FDA based on positive
results from the HERCULES phase 3 study in adults with <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive MS </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris,
March</B><B></B><B>&nbsp;25, 2025</B>. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive
multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September&nbsp;28, 2025. A regulatory submission is also under review in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The regulatory submissions in the US and the EU are supported by the <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7a00e6"><U>results</U></FONT><FONT
STYLE="font-family:arial"> from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of
tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Erik Wallstr&ouml;m, MD, PhD </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Global Head of Neurology Development </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct
inflammatory process in MS.&nbsp;People living with <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over
time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability. The demonstrated ability of tolebrutinib to delay disability by targeting underlying drivers of the disease
represents a potential paradigm shift in treating these patients.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tolebrutinib is currently under clinical investigation, and its safety and efficacy
have not been evaluated by any regulatory authority. The PERSEUS phase 3 study of tolebrutinib in patients with primary progressive MS is currently ongoing with study results anticipated in H2 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About multiple sclerosis </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Multiple
sclerosis is a chronic, immune-mediated, neurodegenerative disease that may result in accumulation of irreversible disabilities over time. The physical and cognitive disability impairments translate into gradual deterioration of health status,
impacting patients&#146; care and quality of life. Disability accumulation remains the significant unmet medical need in MS. To date, the primary target of currently approved medicines has been peripheral B and T cells, while innate immunity within
the CNS, which is believed to drive disability accumulation, remains largely unaddressed. Currently approved or late-stage medicines being tested for MS mainly target the adaptive immune system and/or do not act directly within the central nervous
system to drive clinical benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g939010image2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Living with nrSPMS refers to people with MS who have stopped experiencing relapses but continue to accumulate
disability, experienced as symptoms such as fatigue, cognitive impairment, balance and gait impairment, loss of bowel and/or bladder function, sexual disfunction, amongst others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About tolebrutinib </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tolebrutinib is an
investigational, oral, brain-penetrant, and bioactive Bruton&#146;s tyrosine kinase (BTK) inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS. Unlike currently approved MS therapies
that primarily address peripheral inflammation, tolebrutinib uniquely crosses the blood-brain barrier to achieve therapeutic cerebrospinal fluid concentrations, allowing it to modulate <FONT STYLE="white-space:nowrap">B-lymphocytes</FONT> and
disease-associated microglia within the CNS. This mechanism is believed to address the underlying pathology of progressive MS by targeting the inflammatory processes that contribute to neurodegeneration and disability accumulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Tolebrutinib is being evaluated in phase 3 clinical studies for the treatment of various forms of multiple sclerosis and its safety and efficacy have not been evaluated
by any regulatory authority worldwide. For more information on tolebrutinib clinical studies, please visit <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7a00e6"><U>www.clinicaltrials.gov</U></FONT><FONT STYLE="font-family:arial">.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About HERCULES </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">HERCULES
(clinical study identifier: NCT04411641) was a double-blind randomized phase 3 clinical study evaluating the efficacy and safety of tolebrutinib in patients with nrSPMS. At baseline, nrSPMS was defined as having a SPMS diagnosis with an expanded
disability status scale (EDSS) between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months. Participants were randomized (2:1) to receive either an oral daily dose
of tolebrutinib or matching placebo for up to approximately 48 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary endpoint was <FONT STYLE="white-space:nowrap">6-month</FONT> CDP defined as the
increase of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>1.0 point from the baseline EDSS score when the baseline score is <FONT STYLE="font-family:Times New Roman">&#8804;</FONT>5.0, or the increase of <FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>0.5 point when the baseline EDSS score was &gt;5.0. Secondary endpoints included time to onset of <FONT STYLE="white-space:nowrap">3-month</FONT> CDP as assessed by EDSS score, total number of new or
enlarging T2 hyperintense lesions as detected by MRI, time to onset of confirmed disability improvement, <FONT STYLE="white-space:nowrap">3-month</FONT> change in <FONT STYLE="white-space:nowrap">9-hole</FONT> peg test and <FONT
STYLE="white-space:nowrap">T25-FW</FONT> test as well as the safety and tolerability of tolebrutinib. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About GEMINI 1 and 2
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">GEMINI 1 (clinical study identifier: NCT04410978) and GEMINI 2 (clinical study identifier: NCT04410991) were double-blind randomized phase 3 clinical
studies evaluating the efficacy and safety of tolebrutinib compared to teriflunomide in patients with RMS. Participants were randomized in both studies (1:1) to receive either tolebrutinib and placebo daily or 14mg teriflunomide and placebo. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary endpoint for both studies was the annualized relapse rate for up to approximately 36 months defined as the number of confirmed adjudicated protocol defined
relapses. Secondary endpoints included time to onset of CDW, confirmed over at least 6 months, defined as an increase of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>1.5 points from the baseline EDSS score when the baseline score is 0, an
increase of <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>1.0 point from the baseline EDSS score when the baseline score is 0.5 to <FONT STYLE="font-family:Times New Roman">&#8804;</FONT>5.5 or an increase of <FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>0.5 point from the baseline EDSS score when the baseline score was &gt;5.5 in addition to the total number of new and/or enlarging T2 hyperintense lesions as detected by MRI from baseline through the
end of study, the total number of Gd-enhancing T1 hyperintense lesions as detected by MRI from baseline through the end of study and the safety and tolerability of tolebrutinib. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an innovative
global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.
We provide potentially life-changing treatment options and life-saving vaccine protection to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g939010image2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Sandrine
Guendoul</B> | +33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Nicolas Obrist</B> |
+33 6 77 21 27 55 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>L&eacute;o Le Bourhis</B> | +33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Victor Rouault</B> | +33 6 70 93 71 40 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Timothy Gilbert</B>
| +1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thomas Kudsk
Larsen</B>&nbsp;|+44 7545 513 693 |&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> <B> </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Aliz&eacute; Kaisserian</B>&nbsp;|&nbsp;+33 6 47 04 12 11
|&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> <B> </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Felix Lauscher</B>&nbsp;|&nbsp;+1&nbsp;908&nbsp;612 7239 |&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> <B> </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Keita Browne</B>&nbsp;|&nbsp;+1 781 249 1766
|&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> <B> </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Nathalie Pham</B>&nbsp;|&nbsp;+33 7 85 93 30 17 |&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> <B> </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Tarik Elgoutni</B>&nbsp;| +1 617 710 3587
|&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> <B> </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thibaud Ch&acirc;telet</B>&nbsp;| +33 6 80 80 89 90 |&nbsp;<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Yun Li</B> | +33 6 84 00 90 72 |<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sanofi forward-looking statement</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements
are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that
product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or
obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,&nbsp;trends in exchange rates and prevailing interest rates, volatile economic and
market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk
Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by
applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press
release are the property of the Sanofi group. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g939010image2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d939010dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g939010g01m04.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Chlamydia vaccine candidate granted fast track designation by the US FDA </I></FONT></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or
infertility </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">A phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming days
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris, March</B><B></B><B>&nbsp;26, 2025</B>. The US Food and Drug Administration has granted fast track designation to Sanofi&#146;s mRNA
vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium <I>Chlamydia trachomatis</I>.
Following a promising <FONT STYLE="white-space:nowrap">pre-clinical</FONT> program, Sanofi is planning a phase 1/2 randomized, clinical study designed to evaluate the immunogenicity and safety of the chlamydia vaccine candidate in adults aged 18 to
29 years. The study is due to start in coming days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Jean-Fran&ccedil;ois Toussaint </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Global Head of Vaccines R&amp;D </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;Millions of people currently live with undiagnosed chlamydia, including asymptomatic infection that can also cause
severe long-term health effects if left untreated. Antibiotics to treat chlamydia have not been successful in controlling rising infection rates. With our program we aim to make chlamydia a preventable disease through vaccination.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Chlamydia, caused by the bacterium <I>Chlamydia trachomatis,</I> is a common bacterial infection of the reproductive tract with consequences for developing infertility
and pregnancy complications. In 2020, there were 129&nbsp;million worldwide cases of chlamydia among adults <FONT STYLE="white-space:nowrap">(15-49</FONT> years old), with the highest rates of infection among adolescents and young adults. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although chlamydia can be treated with antibiotics when diagnosed, over 80% of chlamydia cases are asymptomatic, meaning there is a significant risk that infections go
unrecognized, leading to untreated cases and unintentional transmission. Programs that have been put in place to prevent infection rates from rising have proven insufficient, highlighting the urgent public health need for a vaccine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The development of this vaccine candidate is part of the Translational Science Hub, a partnership with the Queensland Government, Griffith University, and the
University of Queensland, connecting world-class researchers in Queensland, Australia, with Sanofi scientists in France and the US. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #bfbfbf">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across
the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g939010image2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine Guendoul</B> | + 33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nicolas Obrist</B> | +
33 6 77 21 27 55 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le Bourhis</B> | + 33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault</B> | + 33 6 70 93 71 40 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert</B>
| + 1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk
Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute; Kaisserian</B> | + 33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher</B> | + 1 908 612 7239 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne</B> | +
1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham</B> | + 33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni</B> | + 1 617 710 3587 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud
Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Yun Li</B>&nbsp;|+ 33 6 84 00 90&nbsp;72&nbsp;|&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements
are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that
product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or
obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market
conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on
our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk
Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by
applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press
release are the property of the Sanofi group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g939010image2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g939010g01m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939010g01m04.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X01>:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M
M,C(Z,#8Z-3,@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0C,V.3<P1D)"13@T,3%%1D%!,#0X,T8R,4$T
M1C$W,D0B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0C,V.3<P1D%"13@T
M,3%%1D%!,#0X,T8R,4$T1C$W,D0B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IC96(T-3@V-2TR.38W+31B,S(M.6)C92UB
M-3(U,C$V9F)C968B('-T4F5F.F1O8W5M96YT240](G5U:60Z-#1B960V-F4M
M9C1E,2TT,SED+6$W.38M-60V.69D,#<Q8CAC(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C@S,3 P-CPO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#DY+C)?,C R
M-%\Q,E\Q-U]$=79A:VET=6<@<&]S:71I=F4@<&AA<V4@,F(@<F5S=6QT<R!D
M96UO;G-T<F%T92!B97-T+6EN+6-L87-S('!O=&5N=&DN9&]C>#PO<F1F.FQI
M/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
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MQ5CY*"8'X>T1^!8^OT!Y]1/FJ:,S9^1LU\ZU[ 44@6'D$9EC OB=PQ]L":/
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MCRR79F6+R'.>SOCSV';++7D$EI0+K+@56V-7T]<_B9/_ "D>'F41A2M"4'T
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MIZ\-CZWN\G99GVE7O;"+"HM<YL$;B^%1SA""W4KN)4/+Y@@]/DWO3I%8L9[
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9H Z .@#H Z .@#H Z .@#H Z .@#H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g939010image2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939010image2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MRKH_@_P_I&@W&C66E0IIUPY>6W;+JY( ).XGLH_*N<S.;T_X4>!H-7DE7P]
MQ0Y59)'=1_P$L1^E '4WGAG1KWQ'8ZW<6*OJ-FFR";<P*#GC ./XCU'>@!;C
MPSH]SXIM?$$UDK:K;1F.*XW-E5PPQC./XF[=Z ,KQ?X%\,^)'2\U;2(KBY7"
M^:&9&(]"5(S^- &O8>&M&T[PX^B6>GQ0:;)$R/"F0&###9/4DCOG- #M&\/Z
M7HNA+I&G6BP6&&'DAB1\Q.>2<\Y- '/V_P +_!<,"QQZ%$%'0>9(?_9J /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
